Shen Xinglei, Parker William, Miller Leah, TenNapel Mindi
Department of Radiation Oncology, University of Kansas Medical Center, 4001 Rainbow Boulevard, Mailstop 4033, Kansas City, KS 66160, USA.
Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.
Ther Adv Urol. 2019 Feb 8;11:1756287219828972. doi: 10.1177/1756287219828972. eCollection 2019 Jan-Dec.
Radiation therapy (RT) is an effective modality for the treatment of squamous cell carcinomas of the penis. The National Comprehensive Cancer Network recommends consideration of primary radiation for penile preservation, in surgically unresectable tumors, and as adjuvant therapy for positive margins, bulky groin nodes or pelvic nodes. We performed a population-based analysis to evaluate the usage of RT in penile cancer from 2007 to 2013.
We used the () database to identify men diagnosed with squamous cell carcinoma of the penis from 2007 to 2013. Patients were grouped as early stage (T1-T2N0), locally advanced (T3-T4N0), node-positive (T1xN1-3) and metastatic. We used linear regression model to test for factors associated with adjuvant radiation in node-positive patients.
We identified 2200 men diagnosed with penile cancer between 2007 and 2013. Of these, 66.4% had early stage, 10.7% had locally advanced, 15.5% had node-positive, 3.2% had metastatic cancer. Among patient with early stage cancer, RT was used in 14 patients (1.0%) and postoperative radiation in an additional 45 patients (3.1%). Among 340 patients with node-positive cancer, 62.1% received surgery alone, 5.6% radiation alone, 21.8% surgery with adjuvant radiation, and 10.6% neither surgery nor radiation. Of patients who had surgery, 26.0% had adjuvant radiation. On univariate analysis, higher nodal stage (N2-3 N1) was associated with adjuvant radiation ( = 0.02), while there was a trend for higher T-stage (T3/T4 T1/T2) ( = 0.08) and history of prior malignancy ( = 0.06). On multivariate analysis, only higher nodal stage (N2-3 N1) was associated with use of adjuvant radiation [hazard ratio (HR) 1.94, = 0.03].
A small percentage of patient who are eligible for primary or adjuvant RT in the United States receive this treatment. Further work should be done to assess barriers to use of radiation in patients with penile cancer.
放射治疗(RT)是治疗阴茎鳞状细胞癌的一种有效方式。美国国立综合癌症网络建议,对于阴茎保留、手术无法切除的肿瘤以及切缘阳性、腹股沟淋巴结肿大或盆腔淋巴结转移的患者,可考虑采用原发性放射治疗作为辅助治疗。我们进行了一项基于人群的分析,以评估2007年至2013年期间放射治疗在阴茎癌治疗中的应用情况。
我们使用()数据库来识别2007年至2013年期间被诊断为阴茎鳞状细胞癌的男性患者。患者被分为早期(T1 - T2N0)、局部晚期(T3 - T4N0)、淋巴结阳性(T1xN1 - 3)和转移性四类。我们使用线性回归模型来测试与淋巴结阳性患者辅助放疗相关的因素。
我们识别出2007年至2013年期间2200名被诊断为阴茎癌的男性患者。其中,66.4%为早期患者,10.7%为局部晚期患者,15.5%为淋巴结阳性患者,3.2%为转移性癌患者。在早期癌症患者中,14名患者(1.0%)接受了放射治疗,另外45名患者(3.1%)接受了术后放疗。在340名淋巴结阳性癌症患者中,62.1%仅接受了手术治疗,5.6%仅接受了放射治疗,21.8%接受了手术及辅助放疗,10.6%既未接受手术也未接受放疗。接受手术的患者中,26.0%接受了辅助放疗。单因素分析显示,较高的淋巴结分期(N2 - 3对N1)与辅助放疗相关(P = 0.02),而较高的T分期(T3/T4对T1/T2)(P = 0.08)和既往恶性肿瘤病史(P = 0.06)有相关趋势。多因素分析显示,只有较高的淋巴结分期(N2 - 3对N1)与辅助放疗的使用相关[风险比(HR)1.94,P = 0.03]。
在美国,符合原发性或辅助性放射治疗条件的患者中,接受这种治疗的比例很小。应进一步开展工作,以评估阴茎癌患者使用放射治疗的障碍。